mCPP Immunoassay Antibody Detection System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting mCPP intake are impractical due to lengthy pre-treatment steps, expensive specialized equipment, and the need for external reference standards, making them unsuitable for clinical and forensic applications, and lack robustness in differentiating between mCPP and its metabolic precursors like trazodone.
Innovation Solution
Development of antibodies specific to mCPP and drugs that produce mCPP as a metabolic product, used in an immunoassay with conjugates and labelling agents for in vitro detection, allowing for the differentiation and quantification of mCPP in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gas chromatography and mass spectroscopy (GC-MS) are used to detect mCPP intake, then measurement precision is improved, but device complexity and ease of operation worsen due to expensive specialized equipment and protracted pre-treatment steps
Solution Approach 1:
The patent replaces the mechanical/chemical GC-MS system with a biological immunoassay system using antibodies that specifically bind to mCPP. This substitution eliminates the need for complex chromatography and mass spectrometry equipment while maintaining detection accuracy through antibody-antigen specificity.
Solution Approach 2:
The patent introduces antibodies as intermediary molecules that mediate the detection of mCPP. These antibodies serve as selective recognition elements that bind specifically to mCPP, enabling accurate detection without requiring complex instrumental analysis or extensive sample preparation.
2Measurement precision
If GC-MS with external reference standards is used, then measurement precision is improved, but ease of operation worsens due to requirement of external reference standards and careful screening
Solution Approach 1:
The immunoassay system is self-sufficient as the antibodies inherently provide the selectivity and specificity needed for accurate detection. The antibody-mCPP binding interaction automatically discriminates between mCPP and its metabolic precursors without requiring external reference standards or complex interpretation protocols.
3Measurement precision
If radioimmunoassay is used to detect mCPP, then sensitivity is improved, but ease of operation worsens due to requirement of radionuclide tracers
Solution Approach 1:
The patent employs non-radioactive detection systems (such as enzymatic labels, fluorescent tags, or colorimetric indicators) that are safer, easier to handle, and do not require special licensing or disposal procedures. These alternative labeling methods maintain sensitivity while eliminating the operational complexities and safety concerns associated with radionuclide tracers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a practical, sensitive, and robust method for the analytical detection and determination of mCPP intake, enabling accurate differentiation from its metabolic precursors, thus enhancing clinical and forensic drug screening capabilities.
Implementation Method 1
Specific binding reactions, such as antibody-antigen interactions, have been used extensively in immunoassays to detect a variety of substances present in tissue extracts.
Data Source
Figure 1
Figure 2
AI summary
The invention describes a practical and robust multi-antibody approach to the sensitive immunodetection and determination of the drug of abuse m-chlorophenyl piperazine (mCPP). The invention also describes methods and kits for mCPP detection in an in vitro sample.